Article

Gene Co-Expression Networks Restructured Gene Fusion in Rhabdomyosarcoma Cancers

Bryan R. Helm\textsuperscript{1}, Xiaohui Zhan\textsuperscript{1,2}, Pankita H. Pandya\textsuperscript{3}, Mary E. Murray\textsuperscript{3}, Karen E. Pollok\textsuperscript{3,4}, Jamie L. Renbarger\textsuperscript{3}, Michael J. Ferguson\textsuperscript{3}, Zhi Han\textsuperscript{4}, Dong Ni\textsuperscript{2}, Jie Zhang\textsuperscript{5,*} and Kun Huang\textsuperscript{1,6,*}

\textsuperscript{1} Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202-3082, USA
\textsuperscript{2} National-Regional Key Technology Engineering Laboratory for Medical Ultrasound, Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, School of Biomedical Engineering, Health Science Center, Shenzhen University, Shenzhen 518060, China
\textsuperscript{3} Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN 46202-3082, USA
\textsuperscript{4} Department of Pharmacology and Toxicology, Indiana University, Indianapolis, IN 46202-3082, USA
\textsuperscript{5} Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202-3082, USA
\textsuperscript{6} Regenstrief Institute, Indianapolis, IN 46202, USA
* Correspondence: jizhan@iu.edu (J.Z.); kunhuang@iu.edu (K.H.)

Received: 17 July 2019; Accepted: 19 August 2019; Published: 30 August 2019

Abstract: Rhabdomyosarcoma is subclassified by the presence or absence of a recurrent chromosome translocation that fuses the \textit{FOXO1} and \textit{PAX3} or \textit{PAX7} genes. The fusion protein (\textit{FOXO1-PAX3/7}) retains both binding domains and becomes a novel and potent transcriptional regulator in rhabdomyosarcoma subtypes. Many studies have characterized and integrated genomic, transcriptomic, and epigenomic differences among rhabdomyosarcoma subtypes that contain the \textit{FOXO1-PAX3/7} gene fusion and those that do not; however, few investigations have investigated how gene co-expression networks are altered by \textit{FOXO1-PAX3/7}. Although transcriptional data offer insight into one level of functional regulation, gene co-expression networks have the potential to identify biological interactions and pathways that underpin oncogenesis and tumorigenicity. Thus, we examined gene co-expression networks for rhabdomyosarcoma that were \textit{FOXO1-PAX3} positive, \textit{FOXO1-PAX7} positive, or fusion negative. Gene co-expression networks were mined using local maximum Quasi-Clique Merger (lmQCM) and analyzed for co-expression differences among rhabdomyosarcoma subtypes. This analysis observed 41 co-expression modules that were shared between fusion negative and positive samples, of which 17/41 showed significant up- or down-regulation in respect to fusion status. Fusion positive and negative rhabdomyosarcoma showed differing modularity of co-expression networks with fusion negative (\(n = 109\)) having significantly more individual modules than fusion positive (\(n = 53\)). Subsequent analysis of gene co-expression networks for \textit{PAX3} and \textit{PAX7} type fusions observed 17/53 were differentially expressed between the two subtypes. Gene list enrichment analysis found that gene ontology terms were poorly matched with biological processes and molecular function for most co-expression modules identified in this study; however, co-expressed modules were frequently localized to cytobands on chromosomes 8 and 11. Overall, we observed substantial restructuring of co-expression networks relative to fusion status and fusion type in rhabdomyosarcoma and identified previously overlooked genes and pathways that may be targeted in this pernicious disease.

Keywords: rhabdomyosarcoma; gene fusion; gene co-expression analysis; quasi-clique merger; copy number variation
1. Introduction

1.1. Gene Fusions in Solid Tumors

Gene fusion is an important consequence of mutation that has been observed in many cancers including malignant solid tumors, leukemia, and especially pediatric sarcoma [1,2]; such fusions may be drivers of, or contribute to cancer progression. Advances in next generation sequencing technologies have empowered a new generation of genomic, transcriptomic, and epigenetic studies of different cancers, and such studies have highlighted the prevalence of structural variation that lead to gene fusions. Recent studies have underscored the important functional roles of gene fusions in sarcoma biology with the promise of providing insights that lead to treatment and improved prognosis. As an example, rhabdomyosarcoma frequently contain recurrent gene fusions involving FOXO1 genes and PAX genes amid a changing landscape of genome mutations and structural variations [3]. The presence of gene fusions reduces patient prognosis because they are associated with aggressiveness of the tumors. While some differential expression analyses have been conducted for gene fusions in pediatric sarcomas [4], relatively few systems biology analyses have been conducted for gene fusions in pediatric sarcomas. The goal of this paper is to implement a systems biology approach for the FOXO1-PAX3/7 fusion in rhabdomyosarcoma using gene correlation network analysis to infer novel biological insights and hypotheses about this aggressive pediatric cancer.

1.2. Rhabdomyosarcoma and the FOXO1-PAX3/7 Fusion

Rhabdomyosarcoma is an aggressive malignancy of soft-tissue that may occur in any non-boney tissue but predominantly arises from striated muscle or myogenic progenitors [5–10]. It is a pediatric cancer with most cases occurring in young patients rather than adults [5–10]. Rhabdomyosarcoma may occur in a diverse range of tissues, several subtypes of which are recognized based on histopathology and presentation of the disease, including botryoid embryonic, spindle embryonic, alveolar, and anaplastic [5,11]. In the aggressive alveolar-type rhabdomyosarcoma, a translocation occurs in the majority of patient cases that results in a fusion of fork-head box 1 (FOXO1) and paired box 3 or paired box 7 (PAX3/7) genes [12,13]. The presence of this fusion has been associated with differences in epigenetic regulatory elements [4,14–17], chromatin content and instability [3,18], copy number variance and structural variation [3,19,20], and gene expression [4,21–23]. FOXO1-PAX3/7 fusion positive tumors have higher mortality fusion negative, and diagnosis can lead to improved risk stratification ([24–26], but see [27]). FOXO1 and the PAX complex of genes encode transcriptional regulation proteins for cell cycle, growth, and development, and their biology may be an important component of FOXO1-PAX3/7’s effects. It is important to note that the histopathological subclassification of rhabdomyosarcomas may be confounded by molecular differences and vice versa. Classically, alveolar rhabdomyosarcoma are differentiated into FOXO1-PAX positive vs. negative; however, embryonic rhabdomyosarcoma are sometimes included with fusion negative alveolar rhabdomyosarcoma, and there is some evidence that these subtypes are indistinguishable clinically [16]. Here, we adopt fusion negative and fusion positive terminology that denotes the presence or absence of FOXO1-PAX3/7 and is agnostic to histopathological designation as the presence or absence of the fusion is integral to understanding how it may change gene correlation networks.

The fusion protein (FOXO1-PAX3/7) contains the activation domain of FOXO1 and full binding domain of PAX3 or PAX7 ([12], reviewed in [28]). DNA binding domains are retained in the fusion protein, which promotes DNA binding and altered gene expression. The fusion protein is expressed and shows strong effects on transcriptional regulation such as (1) PAX3/7 promoted transcription sites become expressed when otherwise silenced early in development; (2) expression is amplified; and (3) the fusion protein localizes to the nucleus ([12], reviewed in [28]). In combination, FOXO1-PAX3/7 becomes a potent transcription regulator that induces downstream changes in gene expression for multiple pathways, including PAX3/7 targets involved in myogenic differentiation, interference with normal FOXO1-signaling, cellular proliferation, apoptosis, and the interplay among
them [7,12,17,28–34]. Presence of the fusion protein alone is insufficient to cause oncogenesis, but it contributes to tumorigenicity and pathogenesis ([28,29] but see [35]).

1.3. Gene Co-Expression Networks and Rhabdomyosarcoma

Many studies have documented changes in gene expression with respect to FOXO1-PAX3/7, including high-throughput expression arrays, manipulation FOXO1-PAX3/7 expression in animal models and cell lines, and integrated -omics based approaches [4,12,15,16,21,23,28]. These studies identified key pathways and processes in rhabdomyosarcoma that may be targeted in treatment, RAS/MEK/ERK pathway in particular [3,6,15,36]. Recently, Sun et al. [4] conducted a comparison of methylation patterns and gene expression for rhabdomyosarcoma with and without FOXO1-PAX3/7. They observed 548 up- and 454 down-regulated genes in FOXO1-PAX3/7 fusion positive samples based on differential expression analysis and a minimum absolute fold change larger than 2. While differential analysis can reveal how gene expression is affected by fusion status, it is often difficult to infer key biological processes or events without also accounting for the relationships among genes. More importantly, co-expression network analysis can identify statistical associations among genes that have not been previously identified by targeted studies and reduce complexity for better biological inference. Inferring both core and differential biological processes by examining their correlations among expressed genes will almost certainly lead to new hypotheses for these rare, understudied cancers and their molecular subtypes.

1.4. Study Overview

For the above reasons, we examined gene co-expression networks in rhabdomyosarcoma with respect to the presence or absence of the FOXO1-PAX3/7 fusion. Gene co-expression network analysis has been widely adopted in bioinformatics to infer gene relationships, predict new gene functions, discover important biological processes, and identify biomarkers for diseases [37–42]. Each gene is treated as a node and among gene correlation coefficients—or a transformation of them—can be calculated and used to weight edges linking genes in the network. Such networks may be mined to define clusters of genes with especially strong co-expression, defined as gene modules and summarized as eigengenes, and enable discovery of genes with highly correlated expression in different conditions. Strongly correlated gene modules within correlation networks often share common biological functions or regulation, e.g., participating in the same biological process or pathway and/or co-regulated by the same transcription factors. The biological implications of gene co-expression modules can often be inferred from gene ontology enrichment analysis. In addition, gene module co-expression can be used for comparative analysis among network modules or in response to different conditions with much greater statistical inference; e.g., in response to fusion status and type. With these potential advantages, we examined the gene correlation networks of gene expression microarrays from the Sun et al. [4] study of fusion negative, FOXO1-PAX3 positive, and FOXO1-PAX7 samples. We identified and compared gene correlation networks as a response to the presence/absence and type of fusion for rhabdomyosarcomas. We hope this translational bioinformatics study leads to new insights about the underlying systems biology, as well as a confirmation of existing knowledge about this pernicious pediatric disease.

In addition to being functionally related, co-expressed genes could also reside on the same cytoband of a chromosome. This is particularly common in cancer samples. Such enrichment of co-expressed genes on specific cytobands often implies copy number variation (CNV) events on these cytobands among the patients. Due to structure proximity, expression levels of genes affected by the same CNV event can be correlated. Given the prevalence of CNV events in cancers, we can also take advantage of gene co-expression network mining to identify potential CNV events. We compared gene co-expression modules that were differentially expressed relative to fusion with CNV information from four new rhabdomyosarcoma cases at Riley Children’s Hospital (Indianapolis, IN, USA). We observed that co-expression modules overlapped significantly with genes that also had copy number variants,
especially those observed in patients that were FOXO1-PAX3/7 negative. These fusion positive patients harbored fewer copy number variants, whereas fusion negative harbored many, which was consistent with previous studies of copy number variance in rhabdomyosarcoma [3,6,8,15,18].

2. Materials and Methods

2.1. Data Source and Pre-Analysis Processing

Gene expression data of rhabdomyosarcoma tissue from 25 patients with fusion-negative type, 26 patients with FOXO1-PAX3 type, and 7 patients with FOXO1-PAX7 type were obtained from NCBI Gene Expression Omnibus (GSE #66533). The determination of fusion status and type are described by Sun et al. [4] and details therein [43]. GEO data was downloaded as robust multiarray average (RMA) normalized probe expression values from an Affymetrix GeneChip Human Genome U133 Plus 2.0 microarray (Thermo Fisher Scientific Inc., Waltham, MA, USA). Gene expression series data were imported into R using the GEOquery package [44] from BioConductor [45].

The raw data contained 54,675 probes mapped to ~35,000 gene symbols; however, multiple probes were matched to the same gene. Probes without gene symbols were removed, and the maximum probe value was used as the gene expression value. Co-expression analysis is based on gene-by-gene regressions which require variance and covariance for meaningful inference [42,46]. For this reason, the genes with expression variance in the bottom 33% quantile were removed to reduce noise in the co-expression analysis and reduce computational demands while retaining many genes for gene co-expression network (GCN) analysis (n = 15,759).

2.2. Gene Co-Expression Network Analysis

All data manipulation and statistical methods were performed using R version 3.5.1 [47] and R packages (described below). Gene co-expression network analysis was performed with local maximum Quasi-Clique Merger (lmQCM), using the R package lmQCM [46]; for theory and background see [41,42,46,48]. lmQCM analysis was implemented with $\gamma = 0.7$, and correlation matrices were calculated using Spearman Rank correlation coefficient.

2.3. Relating Co-Expression Module Expression Variance and Fusion Status

The aim of co-expression analysis was to identify co-expressed gene modules that differed with respect to fusion positive and fusion negative samples. To identify which co-expression modules had differential expression with respect to fusion status, we performed principal component analysis and subsequently analyzed projected loading values using permutational analysis of variance with fusion status (positive vs negative and PAX3 vs. PAX7) as an explanatory variable. First, principal components analysis was performed separately for each co-expression module and sample loading values were calculated for each principal component. In this analysis, the first principal component represented the axis of greatest gene expression variation for each module. Next, the among sample distance matrix of loading values were calculated and treated as a response variable using permutational analysis of variance with fusion status as an explanatory variable using the adonis function from the vegan package for R [49]. Co-expression modules were considered as associated with fusion status and type differences when $p < 0.05$. This analysis probes the degree to which gene expression variance is explained by fusion status of co-expressed modules common to all rhabdomyosarcoma samples, i.e., differential expression is implied by a significant effect of fusion status.

A key difference between lmQCM and other gene co-expression network algorithms is that it allows genes to belong to multiple co-expressed modules, i.e., gene overlap is permitted. Genes that are merged into multiple modules may represent genes that integrate related but interactively distinct gene interaction networks. Thus, gene overlap among the 4 largest upregulated and 4 largest downregulated co-expression were identified and described to identify genes that link co-expressed modules.
Gene co-expression analysis was performed on fusion negative and fusion positive samples separately to compare overall metrics of network structure: module count and size. Because fusion positive samples were potentially confounded by two unique PAX fusion types with unique GCNs, fusion positive samples were secondarily investigated for differential co-expression between PAX3 and PAX7-type fusions (See Section 2.2 for details). While not a primary aim of the manuscript, we observed that several co-expression modules were differentially regulated between the two fusion types.

2.4. Functional Enrichment Analysis

Modules that showed an association between expression variance and fusion status were subsequently analyzed for functional enrichment and co-expression atlas using ToppFunn (https://toppgene.cchmc.org/). Gene ontology (GO), cytoband analysis, and co-expression atlas terms that were considered statistically significant if the false discovery rate (FDR) < 0.05. In addition, we performed pathway analysis using Ingenuity® Pathway Analysis (https://www.qiagenbioinformatics.com/) from QIAGEN, Inc. (Venlo, The Netherlands) for gene modules that were significantly associated with PAX3 and PAX7 differences from fusion positive network analysis. This was performed in addition to ToppFunn enrichment analysis because these gene modules had low affinity for specific biological processes and co-expression atlas annotations, and such an analysis can highlight additional information about identified gene networks.

2.5. Copy Number Variation in Rhabdomyosarcoma

Four rhabdomyosarcoma cancer samples were sequenced using Illumina platform with the data processed using the BWA-SAMBLASTER-GATK pipeline. This analysis generated a VCF file that included copy number alteration and breakpoint coverage for rhabdomyosarcoma samples. Based on the structural variation data, one of the four samples harbored the FOXO1-PAX3 gene fusion. Based on the copy number alteration data, a circular binary segmentation (CBS) analysis was performed using the R package DNAcopy [50]. Segments were mapped to reference hg19 genome assembly. Gene-level copy number variation (CNV) was estimated using the GISTIC2 method [51]. Genes were categorized as having copy number variation based on when CNV ≥ 0.2 or ≤ 0.2. Genes with CNV values ≤ 0.2 were categorized as deletion and ≥ 0.2 were categorized as amplifications (based on [52]).

The list of genes with significant copy number variation from both fusion negative and positive samples were compared with the genes mapped into co-expression modules (see above). Counts of gene overlap were analyzed using Fisher’s exact test and a p < 0.05 for statistical significance.

3. Results

3.1. Consensus Network Analysis of Fusion-Associated Module Expression Patterns

ImQCM consensus network analysis identified 41 gene co-expression modules that were shared in fusion negative and positive samples (Table S1). A subset of these modules had a statistically significant relationship between fusion status and gene co-expression patterns (Figure 1, Table 1). 4/17 modules contained upregulated genes in FOXO-PAX3/7 positive samples, whereas 13/17 contained downregulated genes (Figure 1 and Figure S1).
Figure 1. Gene expression heatmaps of co-expression modules that were identified from consensus ImQCM network modeling and that showed differential gene regulation with respect to FOXO1-PAX3/7 fusion status (see Table 1). Expression values have been organized by hierarchical clustering to better visualize absolute expression values (left). To better visualize potential differences between PAX3 and PAX7 type fusions, gene expression values were mean centered and normalized from −1 to 1 for each module separately (right).

Table 1. Differential co-expression analysis of modules that were significantly different in fusion negative vs positive cases. For brevity, only modules with significant ($p < 0.05$) differences are reported (see Table S1 for full results).

| Module | Gene Count | $p$  |
|--------|------------|------|
| 3      | 576        | 0.001|
| 4      | 459        | 0.001|
| 5      | 334        | 0.001|
| 9      | 118        | 0.001|
| 10     | 84         | 0.001|
| 15     | 33         | 0.005|
| 19     | 24         | 0.001|
| 23     | 17         | 0.038|
| 24     | 17         | 0.001|
| 27     | 15         | 0.001|
| 31     | 13         | 0.017|
| 34     | 12         | 0.001|
| 35     | 11         | 0.001|
| 36     | 11         | 0.001|
| 38     | 10         | 0.001|
| 39     | 10         | 0.001|
| 40     | 10         | 0.019|
Modules 3, 24, 34, and 40 showed elevated expression values in FOXO1-PAX3/7 positive samples compared to fusion negative (Figure 1). There was limited overlap among the gene names for these 4 co-expression modules, especially compared with fusion negative networks (Figure 2). 5/17 genes from module 24 and 3/12 genes from module 34 were co-expressed in module 3; however, no other overlaps for these modules were observed (Figure 2A). Overlap genes in modules 3 and 24 were PROX1, CD82, PGBD5, SCN4A, and LINC00689; overlap genes in modules 3 and 34 were BMS1P6, BMS1P5, and RP11-235E17.4. Of these genes, several may be important for rhabdomyosarcoma, including a homeobox transcription factor (PROX1), a tumor suppressor (CD82), a transposable element (PDBD5), a muscle sodium channel (SCN4A), and a long intergenic non-coding RNA (LINC00689) (see Discussion).

Figure 2. Venn diagrams of gene counts and overlap for co-expression modules that were upregulated (A) and downregulated (B) in rhabdomyosarcoma samples that were positive for the FOXO1-PAX3/7 fusion.

Modules 4, 5, 9, 10, 15, 19, 23, 27, 34, 35, 36, 38, and 39 contained genes that were downregulated in FOXO1-PAX3/7 positive samples compared to fusion negative. Many genes were co-expressed in more than one module (Figure 2B), indicating these modules had substantial overlap compared with fusion positive (Figure 2). Nine genes were observed in at least three of the modules, though no single gene appeared in all four. Genes that overlapped with three of the modules were FADD, DPAGT1, FAM118B, SDHAF2, TMEM138, KIF16B, DDOST, CCDC86, and TBL2 (Figure 2). Of genes identified in this manner, TMEM138 and FADD are both important for cell cycle, proliferation, and oncogenesis (see Discussion).

3.2. Gene Ontology, Cytoband, and Co-Expression Atlas

Gene names from modules associated with fusion status were submitted to ToppGene functional enrichment analysis. The top gene ontology term and cytoband location for each module are reported in Table 2. Many of the modules did not match to specific gene ontology functions and only 8/17 co-expression modules had statistically significant GO term mapping (Table 2 and Table S2). Gene
module 3, which was upregulated in fusion positive samples, returned no biological processes as enriched. Genes from this module were significantly localized to cytobands on chromosomes 9, 10, and 16. In contrast, downregulated modules 4, 5, 9, and 10—all downregulated in fusion positive samples—return biological process enrichments for RNA processing, developmental pathways, and Golgi-related pathways. Modules 4, 5, and 9 were strongly associated with cytobands on chromosomes 8 and 11, while module 10 showed localization to chromosome 19.

Table 2. Gene list enrichment analysis of biological processes and cytoband locations 5 largest differentially co-expressed gene modules in fusion negative and fusion positive samples (See Table S2 for all differentially co-expressed modules). Module 3 was upregulated, whereas Modules 4, 5, 9, and 10 were downregulated.

| Module | GO ID | Biological Process                          | FDR B&Y | Cytoband             | FDR B&Y |
|--------|-------|---------------------------------------------|---------|----------------------|---------|
| 3      | NA    | NA                                          | NA      | 9p21.11              | <0.0001 |
|        |       |                                             |         | 16p12.3              | <0.0001 |
|        |       |                                             |         | 16p12.2              | <0.001  |
|        |       |                                             |         | 10q26                | <0.001  |
| 4      | 6369  | RNA Processing                              | <0.0001 | 8q24.3               | <0.0001 |
|        | 34660 | ncRNA metabolic process                      | <0.0001 | 11q13                | <0.0001 |
|        | 34470 | ncRNA processing                            | <0.0001 | 11q21                | <0.0001 |
|        | 22613 | ribonucleoprotein complex biogenesis         | <0.0001 | 8q24.13              | <0.0001 |
|        | 70647 | protein conjugation by conjugation or removal| <0.0001 | 8p21.3               | <0.001  |
| 5      | 9790  | embryo development                           | <0.0001 | 11q13                | <0.001  |
|        | 35295 | tube development                             | <0.0001 | 11q21                | <0.001  |
|        | 31175 | neuron projection development                | <0.0001 | 11p15.3              | 0.012   |
|        | 22008 | neurogenesis                                 | <0.0001 | 7q21                 | 0.046   |
|        | 45595 | regulation of cell differentiation           | <0.0001 |                     |         |
| 9      | 6890  | retrograde vesicle transport                 | <0.0001 | 11q13                | <0.0001 |
|        | 48193 | Golgi transport                              | <0.0001 | 11p15.3              | <0.0001 |
|        | 6888  | ER to Golgi vesicle transport                | <0.0001 | 11q12.2              | <0.001  |
|        | 30968 | endoplasmic reticulum unfolded protein       | <0.001  | 11p15.5-4            | <0.01   |
|        | 6986  | response to unfolded protein                 | <0.001  | 11p12-p11            | <0.01   |
| 10     | 6396  | RNA Processing                              | <0.01   | 19p13.3              | <0.0001 |
|        | 22613 | ribonucleoprotein complex biogenesis         | <0.01   | 19p13.11             | <0.0001 |
|        | NA    | NA                                          | NA      | 19p13.2              | <0.0001 |
|        |       |                                             |         | 19p13.32             | <0.01   |

Co-expression modules that did not return results from gene enrichment analysis were labeled with the abbreviation “NA” for not available. Processes reported do not directly correspond to cytoband locations reported.

Co-expression Atlas enrichment analysis revealed that co-expression modules contained genes with known differential regulation due to FOXO1-PAX3/7 fusion and annotations related to cancer more generally (Table 3 and Table S3). Module 3 returned annotations are defined as genes upregulated in rhabdomyosarcoma that harbor or commonly contain the FOXO1-PAX3/7 fusion and 1 annotation that contains genes downregulated with FOXO1-PAX3/7 is knocked down in cell lines. Module 5 returned annotations that are commonly downregulated when the FOXO1-PAX3/7 fusion is present. Interestingly, genes annotated as developmental or related to stem cells were observed among most co-expression modules, and module 4 contained annotations suggesting broader connections to cancer.
Table 3. Top results of ToppGene co-expression analysis for the 5 largest co-expressed modules identified by consensus lmQCM analysis (See Table S3 for more detailed table).

| Module | Input # | ID | Name                                                                 | p       |
|--------|---------|----|----------------------------------------------------------------------|---------|
| 3      | 576     | M2012 | Genes up-regulated in alveolar rhabdomyosarcoma compared to embryonic rhabdomyosarcoma | < 0.0001|
| 4      | 475     | 15902281—Table S1A | Human Leukemia Schoch05 | < 0.0001|
| 5      | 326     | M8519 | Genes down-regulated in alveolar rhabdomyosarcoma compared to embryonic rhabdomyosarcoma | < 0.0001|
| 9      | 121     | 15902281—Table S1B | Human Leukemia Schoch05 | < 0.0001|
| 10     | 80      | FacebaseRNAseq e8.5 Hind Brain Neural Epithelium top-relative-expression-ranked 2500 k-means-cluster#2 | < 0.0001|

3.3. lmQCM of Fusion Negative and Fusion Positive Gene Co-Expression Networks

We performed lmQCM network analysis on gene expression data on FOXO1-PAX3/7 positive and negative samples separately to assess the degree to which network modularity was affected by fusion. This identified 53 co-expression modules in FOXO1-PAX3/7 positive samples that contained a median of 17 and mean of 138.9 genes. 109 co-expression modules were identified in fusion negative samples with a median of 13 and mean of 70.4 genes. Unexpectedly, several of the co-expression modules from the fusion positive gene correlation network were differentially co-expressed PAX3- versus PAX7-type fusion positive samples (Figure 3). As with consensus network analysis, modules-of-interest were sorted using PCA and permutational Anova analysis. For 17/53 co-expression modules, fusion status—but here, PAX3 vs PAX7 type fusions—caused differential regulation of co-expressed gene modules (Table 4 and Table S4).

Figure 3. Gene expression heatmaps of co-expression modules that were identified from lmQCM network analysis of FOXO1-PAX3/7 positive samples and that showed differential gene regulation between PAX3 and PAX7 cases. Expression values were organized by hierarchical clustering to better visualize absolute expression values (left). To see potential differences between PAX3 and PAX7 type fusions, gene expression values were normalized (right).
Table 4. Differential co-expression analysis of modules that were significantly different in PAX3 vs PAX7 fusion positive patients. For brevity, only modules with significant ($p < 0.05$) differences are reported (see Table S4 for full results).

| Module | Gene Count | $p$  |
|--------|------------|------|
| 5      | 178        | 0.002|
| 7      | 148        | 0.006|
| 9      | 84         | 0.016|
| 10     | 72         | 0.002|
| 11     | 62         | 0.001|
| 15     | 37         | 0.004|
| 17     | 32         | 0.038|
| 24     | 19         | 0.03 |
| 25     | 18         | 0.001|
| 26     | 18         | 0.011|
| 28     | 16         | 0.015|
| 33     | 14         | 0.001|
| 36     | 13         | 0.001|
| 39     | 12         | 0.004|
| 41     | 11         | 0.008|
| 44     | 11         | 0.022|
| 47     | 10         | 0.045|
| 50     | 10         | 0.05 |

We further examined the co-expression modules that were differentially regulated between PAX3- and PAX7-type and observed that FOXO1 appeared in modules 7 and 10, which were differentially upregulated in PAX7 fusions. These genes had expression values that were ~2× higher in PAX7 versus PAX3-type fusions. In contrast to FOXO1-PAX3 type fusions, FOXO1-PAX7 fusions did not associate with co-expression annotations related to prior rhabdomyosarcoma studies when queried using gene enrichment analysis. To better understand how FOXO1 signaling within these co-expression modules may drive network-level differences in PAX7-type, we implemented Ingenuity Pathway Analysis to map known and inferred relationships among these key genes in the presence of the FOXO1-PAX7 fusion (Figure 4). This analysis revealed that the PAX7-specific fusion was associated with an upregulation of BCL2—a critical component of apoptosis (Figure 4A).

Figure 4. The network visualization of pathway analysis for modules 7 (A) and 10 (B) from fusion positive network analysis. All genes were upregulated in PAX7 samples compared to PAX3; however, the degree to which genes were upregulated varied. Genes with green coloration had higher log$_2$-fold change. Solid lines indicate a direct relationship between two genes, whereas dashed lines indicate an indirect predicted relationship. FOXO1 and PAX7 were important genes for both modules and showed 2-fold and 3-fold increase respectively in PAX7 samples.
3.4. Copy Number Variation

We performed whole genome sequencing on four rhabdomyosarcoma samples. One sample was positive for the FOXO1-PAX3/7 gene fusion, and three samples were negative. Copy number variation analysis using a log change value >0.2 resulted in 306 amplifications and 239 deletions for the fusion positive sample. The fusion negative samples had 8746, 7883, 6514 amplifications and 8284, 4214, 1565 deletions, respectively.

3.5. Copy Number Variation in Gene Modules from Consensus Network

We examined whether genes with CNV were clustered into one or more co-expression modules from consensus network analysis by comparing overlap. Few co-expression modules with differential expression showed overlapping copy number variation. However, co-expression modules 4 and 5 each had a statistically significant count of genes that also have significant CNV (Table 5). These gene expression modules were significantly associated with multiple cytobands on chromosomes 8 and 11 (Table 2).

Table 5. Count overlap of genes with significant copy number variation and consensus ImQCM co-expression modules that showed statistically significant association with fusion status.

| Module | Total Gene Count | Genes with CNV | p     |
|--------|-----------------|----------------|-------|
| 3      | 576             | 37             | 0.657 |
| 4      | 459             | 157            | <0.0001 |
| 5      | 334             | 44             | <0.0001 |
| 9      | 118             | 10             | 0.241 |
| 10     | 84              | 4              | 0.819 |
| 15     | 33              | 4              | 0.132 |
| 19     | 24              | 0              | 0.398 |
| 23     | 17              | 0              | 0.621 |
| 24     | 17              | 1              | 1     |
| 27     | 15              | 0              | 1     |
| 31     | 13              | 0              | 1     |
| 34     | 12              | 0              | 1     |
| 35     | 11              | 0              | 1     |
| 36     | 11              | 0              | 1     |
| 38     | 10              | 1              | 0.46  |
| 39     | 10              | 0              | 1     |
| 40     | 10              | 1              | 0.46  |
| 41     | 10              | 0              | 1     |

Statistical values reported from Fisher’s Exact Test.

4. Discussion

We observed co-expressed gene modules that were also differentially regulated with respect to fusion status in rhabdomyosarcoma. Many of the genes that were co-expressed in these modules have been implicated in previous studies of differential expression analyses ([4], especially [22]). Congruence between existing differential expression studies and this network analysis help validate the patterns described and discussed in this study. For example, module 3 contained 139/331 genes upregulated in alveolar compared to embryonic rhabdomyosarcoma, 27/48 genes that were downregulated when FOXO1-PAX3 was altered with RNA interference, and 22/64 genes previously associated with cell line differences related to PAX3 and PAX7 fusions (Table 4 and Table S4). Module 5 contained 75/182 genes that were downregulated in alveolar versus embryonic, and 50/408 genes that were downregulated when FOXO1-PAX3 was overexpressed in mouse models. Because co-expression analysis identifies correlations among genes, genes that have differential expression, but are not strongly correlated with large modules, are not considered here. This could explain why some annotated genes were missing from gene co-expression modules identified in the current study. However, co-expressed genes that were not identified in previous investigations—perhaps due to selection criteria, restrictions
of gene expression information, or because relationships among genes were not accounted for—may harbor undiscovered FOXO1-PAX3/7 genes and pathways, which in turn may contain novel targetable pathways for rhabdomyosarcoma.

Many of the gene co-expression modules from consensus analysis also matched with developmental, stem cell, and cancer genes. Modules 4 and 9 contained genes related to leukemia and hepatoblastoma and had significant mapping to chromosomes 8 and 11 (Tables 2 and 3, Tables S2 and S3). These results suggest that FOXO1-PAX3/7 positive rhabdomyosarcoma show differential expression for genes that are broadly co-expressed in cancers, perhaps representing core growth and proliferative pathways common to oncogenesis. Interestingly, gene enrichment analysis returned developmental and stem cell genes, based on annotations from Davicioni et al. [22]. PAX genes are normally a component of embryogenesis, and recent studies have explored the relationship between PAX fusions, myogenic differentiation, and muscular phenotypes common in rhabdomyosarcoma [4,6,15–17]. These studies have described in detail how activation of myogenic transcription factors downstream of PAX, as well as methylation status combine to elucidate the manners in which biological patterns determined by functional mechanisms in rhabdomyosarcoma subtypes. Thus, co-expression modules from our gene correlation network analysis recapitulate known biological phenotypes and mechanisms underlying rhabdomyosarcoma.

A potentially important phenomenon for modeling gene interaction networks is that some genes may interact for two or more co-expression modules. lmQCM is quite different from other gene co-expression network mining algorithms in that it can assign a gene to multiple co-expression modules, which is not the case for hierarchical-based module detection. This helps identify the degree to which different co-expression modules are integrated vs dis-integrated in different conditions. For example, we observed different degrees of overlap in downregulated versus upregulated co-expression modules that were also differentially expressed in fusion negative and fusion positive samples. Upregulated genes tended to act more cohesively as a network with one large module and few small modules that showed low to moderate overlap. This result suggests that co-expression patterns of upregulated genes were driven by stronger correlations that were merged by the lmQCM algorithm.

Importantly, investigating which genes belong to multiple modules may lead to important new biological insights that have been neglected or overlooked by studies that do not permit gene membership in multiple modules. Co-expressed, upregulated genes that were members of multiple modules included a homeobox transcription factor (PROX1), a tumor suppressor (CD82), a transposable element (PDBD5), a muscle sodium channel (SCN4A), and a long intergenic non-coding RNA (LINC00689). Downregulated modules had co-expression modules with substantially more overlap than upregulated genes (Figure 2). Genes that overlapped with 3 of the 4 largest downregulated modules were identified and included oncogenic genes, e.g., TMEM138, as well as externally mediated apoptosis, e.g., FADD (Figure 2). FADD is a particularly important gene to identify in this analysis because it mediates FAS-associated cell death and is downregulated along with 3 somewhat distinct co-expression modules. A prior study documented resistance to FAS-mediated cell death in alveolar rhabdomyosarcoma cell lines and proposed that targeting the FAS-pathway may lead to treatments for rhabdomyosarcoma with gene fusion [53]. Our analysis rediscovered FADD.

It is worthwhile to point out that we also tested the widely used Weighted Gene Correlation Network Analysis (WGCNA) R package for GCN module discovery [37,54] and WGCNA generates large modules with hundreds to thousands of genes without being able to detect the smaller GCN modules, suggesting that lmQCM is particularly suitable for discovering small overlapping GCN modules with biological implications. This study is a particularly important and unique demonstration of lmQCM’s ability to assign genes as components of multiple networks and how identification of such genes may lead to important biological insights.

Though we focused on identifying co-expressed gene expression in response to fusion status for this study, lmQCM analysis can also reveal important overall network differences in different conditions. For example, the fusion negative gene correlation network had more, smaller modules
compared to fusion positive. This suggests that either gene-level expression correlations were not strong enough to merge smaller modules by lmQCM compared to FOXO1-PAX3/7.

Surprisingly, lmQCM network analysis of fusion positive samples also returned modules that were differentially regulated between PAX3 and PAX7 fusions. This is an important contribution to the literature about rhabdomyosarcoma because differences between fusion types are far less studied than fusion presence more generally. Based on gene list enrichment, some of the genes in differentially regulated modules have been reported by prior studies, e.g., 18 genes have been previously associated PAX3 or PAX7 expression variance (Table S5). However, most of these genes from differentially co-expression fusion positive modules reported no known responses to PAX3 or PAX7 in rhabdomyosarcoma or other cancers. Many, if not most, studies of FOXO1-PAX fusion in rhabdomyosarcoma combine these two fusion subtypes, and few studies have PAX3 may differ from PAX7. Here, we show that PAX3 vs PAX7 differences may be widespread to gene co-expression with many of genes having higher expression levels in PAX7 (Figure 3). For example, FOXO1 and PAX7 were both returned as differentially co-expressed in this analysis, which may have important mechanistic explanations for differences between molecular subtypes. Interestingly, PAX7 fusion caused an upregulation of BCL2—an apoptosis regulator—that was comparatively downregulated in PAX3-type fusions. Prior reports have implicated BCL2 as a potential target for pharmaceuticals in fusion positive rhabdomyosarcoma [55]. While further validation of this pattern is necessary, this may suggest that apoptosis pathways have altered expression in fusion subtypes.

Importantly, many co-expression modules were not differentially regulated with respect to fusion status (positive/negative), though there may be graphically distinct patterns that occur among samples (Figure S2). Rhabdomyosarcoma is a diverse syndrome of rare cancers, so many other confounding variables may influence the expression of these co-expressed genes such as stage, tissue of origin, tissue heterogeneity, additional genetic mutations, or other markers of disease progression. Future studies may seek to associate phenotypic, more comprehensive molecular, and clinical data with co-expression modules from these rare diseases. Such investigations may find that disease prognosis, staging, and/or mutational variance are associated with co-expression modules identified in the present study, which were not associated with the FOXO1-PAX3/7 fusion.

5. Conclusions

The FOXO1-PAX3/7 fusion results in a novel transcriptional regulator that introduces novel interactions among expressed genes. Prior studies have identified many genes that are differentially regulated with respect the presence or absence of FOXO1-PAX3/7 gene fusion in rhabdomyosarcoma using both experimental and clinical data. But the differential expression analyses that are commonly used to identify fusion biomarkers are agnostic with respect to gene interactions. Here we show that previously implicated genes are frequently co-expressed as networks of genes, raising the issue of whether co-expressed genes are drivers or passengers. Our study importantly rediscovered differential regulation of key apoptotic genes among co-expressed modules that have been previously targeted by pharmaceutical development for rhabdomyosarcoma, though existing literature is limited. Future work may consider how these pharmaceutical agents affect expression for gene co-expression networks as identified in the present study. We also describe many genes that were differentially co-expressed in PAX3 versus PAX7 fusions. While the FOXO1-PAX fusion has been well-studied, information about differences between fusion types are generally limited. Here, we provide evidence of heretofore unexplored gene interaction networks that differ between fusion types. More importantly, modules described herein provide evidence that FOXO1-PAX3/7 fusion affects not only differential expression of individual genes, but also the interactions among them, which moves beyond the gene-by-gene centric analyses that are commonly conducted. Future work could validate the differences identified by network analysis as a means of discovering and understanding mechanistic differences among fusion subtypes in rhabdomyosarcoma. Implementing a diversity of analytical approaches can lead to exciting, new hypotheses regarding the functional and genetic roles of the FOXO1-PAX3/7 fusion.
in rhabdomyosarcoma, for which we plan to test experimentally using patient-derived cell and PDX models. Such discoveries will shed light on the development of personalized treatment for this rare, aggressive cancer, and promote similar research in other pediatric cancers.

Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4425/10/9/665/s1, Table S1: Differential expression analysis by PCA for co-expressed modules in rhabdomyosarcoma patients with and without FOXO1-PAX3/7 fusion with full report of statistics from permutational Anova, Table S2: Gene list enrichment of biological process and cytoband locations for gene co-expression modules that were differentially regulated in fusion positive versus fusion negative rhabdomyosarcoma, Table S3: Expanded Co-expression Atlas results from gene list enrichment analysis with ToppFunn for 5 largest differentially regulated co-expression modules in fusion negative versus positive rhabdomyosarcoma, Table S4: Differential expression analysis by PCA for co-expressed modules in rhabdomyosarcoma patients with FOXO1-PAX3/7 fusion, Table S5: Top 5 Co-expression Atlas (ToppFunn) results from gene list enrichment for genes that were differentially co-expressed PAX3 versus PAX7 fusion positive rhabdomyosarcoma, Figure S1: The distribution of max gene expression values per probe and within gene expression variance of raw data from GSE6533, Figure S2: Heatmap plots of normalized gene expression values for 41 co-expression modules that were identified using lmQCM network analysis.

Author Contributions: The study was designed and conceived by B.R.H., X.Z., J.Z., and K.H. Sequencing data were collected and provided by P.H.P., M.E.M., K.E.P., J.L.R., and M.J.F., and copy number analysis was lead and written by X.Z. Z.H. and D.N. provided computational support, and funding was provided by J.L.R., D.N., Z.H., J.Z., K.H. The manuscript was prepared and edited by B.R.H., X.Z., J.Z., and K.H.

Funding: This work was partially supported by Indiana University Precision Health Initiative to BH, JZ, ZH; NCI ITCR U01CA188547 to KH; NIH U54 HD090215 to PP, MM, KP, MF, and JR; and the Shenzhen Peacock Plan (KQTD2016053112051497) to XZ and DN.

Acknowledgments: Comments, criticism, and helpful suggestions to improve research and manuscript writing were provided by M. Marshall, T. Johnson, C. Yu, and D. Wang. Z. Huang wrote and helped troubleshoot the lmQCM package implementation for this manuscript, and S. Xiang provided advice for statistical analysis.

Conflicts of Interest: The authors declare no conflicts of interest.

References

1. Mitelman, F.; Johansson, B.; Mertens, F. The impact of translocations and gene fusions on cancer causation. Nat. Rev. Cancer 2007, 7, 233–245. [CrossRef] [PubMed]
2. Nguyen, T.H.; Barr, F.G. Therapeutic Approaches Targeting PAX3-FOXO1 and Its Regulatory and Transcriptional Pathways in Rhabdomyosarcoma. Molecules 2018, 23, 2798. [CrossRef] [PubMed]
3. Shern, J.F.; Chen, L.; Chmielecki, J.; Wei, J.S.; Patidar, R.; Rosenberg, M.; Ambrogio, L.; Auclair, D.; Wang, J.; Song, Y.K.; et al. Comprehensive Genomic Analysis of Rhabdomyosarcoma Reveals a Landscape of Alterations Affecting a Common Genetic Axis in Fusion-Positive and Fusion-Negative Tumors. Cancer Discov. 2014, 4, 216–232. [CrossRef] [PubMed]
4. Sun, W.; Chatterjee, B.; Wang, Y.; Stevenson, H.S.; Edelman, D.C.; Meltzer, P.S.; Barr, F.G. Distinct methylation profiles characterize fusion-positive and fusion-negative rhabdomyosarcoma. Mod. Pathol. 2015, 28, 1214–1224. [CrossRef] [PubMed]
5. Raney, R.B.; Anderson, J.R.; Barr, F.G.; Donaldson, S.S.; Pappo, A.S.; Qualman, S.J.; Wiener, E.S.; Maurer, H.M.; Crist, W.M. Rhabdomyosarcoma and Undifferentiated Sarcoma in the First Two Decades of Life: A Selective Review of Intergroup Rhabdomyosarcoma Study Group Experience and Rationale for Intergroup Rhabdomyosarcoma Study V. J. Pediatr. Hematol. Oncol. 2001, 23, 215–220. [CrossRef] [PubMed]
6. Seki, M.; Nishimura, R.; Yoshida, K.; Shimamura, T.; Shiraishi, Y.; Sato, Y.; Kato, M.; Chiba, K.; Tanaka, H.; Hoshino, N.; et al. Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma. Nat. Commun. 2015, 6, 1–8. [CrossRef]
7. Drummond, C.J.; Hanna, J.A.; Garcia, M.R.; Devine, D.J.; Heyrana, A.J.; Finkelstein, D.; Rehg, J.E.; Hatley, M.E. Hedgehog Pathway Drives Fusion-Negative Rhabdomyosarcoma Initiated From Non-myogenic Endothelial Progenitors. Cancer Cell 2018, 33, 108–124.e5. [CrossRef]
8. Skapek, S.X.; Ferrari, A.; Gupta, A.A.; Lupo, P.J.; Butler, E.; Shipley, J.; Barr, F.G.; Hawkins, D.S. Rhabdomyosarcoma. Nat. Rev. Dis. Prim. 2019, 5, 1. [CrossRef]
9. Spunt, S.L.; Skapek, S.X.; Coffin, C.M. Pediatric Nonrhabdomyosarcoma Soft Tissue Sarcomas. Oncologist 2008, 13, 668–678. [CrossRef]
10. Dziuba, I.; Kurzawa, P.; Dopierała, M.; Larque, A.B.; Januszkiewicz-Lewandowska, D. Rhabdomyosarcoma in children—current pathologic and molecular classification. Pol. J. Pathol. 2018, 69, 20–32. [CrossRef]

11. Horn, R.C.; Enterline, H.T. Rhabdomyosarcoma: A clinicopathological study and classification of 39 cases. Cancer 1958, 11, 181–199. [CrossRef]

12. Mercado, G.E.; Barr, F.G. Fusions Involving PAX and FOX Genes in the Molecular Pathogenesis of Alveolar Rhabdomyosarcoma: Recent Advances. Curr. Mol. Med. 2007, 7, 47–61. [CrossRef] [PubMed]

13. Giese, W.; Eigel, M.; Westerheide, S.; Engwer, C.; Klipp, E. Influence of cell shape, inhomogeneities and diffusion barriers in cell polarization models. Phys. Biol. 2015, 12, 0066014. [CrossRef] [PubMed]

14. Ciesla, M.; Dulak, J.; Józkowicz, A. MicroRNAs and epigenetic mechanisms of rhabdomyosarcoma development. Int. J. Biochem. Cell Biol. 2014, 53, 482–492. [CrossRef] [PubMed]

15. Stewart, E.; McEvoy, J.; Wang, H.; Chen, X.; Honnell, V.; Ocarz, M.; Gordon, B.; Dapper, J.; Blankenship, K.; Yang, Y.; et al. Identification of Therapeutic Targets in Rhabdomyosarcoma through Integrated Genomic, Epigenomic, and Proteomic Analyses. Cancer Cell 2018, 34, 411–426.e19. [CrossRef] [PubMed]

16. Sun, W.; Chatterjee, B.; Shern, J.F.; Pattidar, R.; Song, Y.; Wang, Y.; Walker, R.L.; Pawel, B.R.; Linardic, C.M.; Houghton, P.; et al. Relationship of DNA methylation to mutational changes and transcriptional organization in fusion-positive and fusion-negative rhabdomyosarcoma. Int. J. Cancer 2019, 144, 2707–2717. [CrossRef] [PubMed]

17. Gryder, B.E.; Yohe, M.E.; Chou, H.C.; Zhang, X.; Marques, J.; Wachtel, M.; Sen, N.; Song, Y.; Gualtieri, A.; et al. PAX3-FKHR establishes myogenic super enhancers and confers BET bromodomain vulnerability. Cancer Discov. 2017, 7, 884–899. [CrossRef]

18. Vicente-García, C.; Villarjo-Balcells, B.; Trastorza-Azzárate, I.; Naranjo, S.; Acemel, R.D.; Tena, J.J.; Rigby, P.W.J.; Devos, D.P.; Gómez-Skarmeta, J.L.; Carvajal, J.J. Regulatory landscape fusion in rhabdomyosarcoma through interactions between the PAX3 promoter and FOXI1 regulatory elements. Genome Biol. 2017, 18, 106. [CrossRef]

19. Reichek, J.L.; Duan, F.; Smith, L.M.; Gustafson, D.M.; O’Connor, R.S.; Zhang, C.; Dunlevy, M.J.; Gastier-Foster, J.M.; Barr, F.G. Genomic and clinical analysis of amplification of the 13q31 chromosomal region in alveolar rhabdomyosarcoma: A report from the children’s oncology group. Clin. Cancer Res. 2011, 17, 1463–1473. [CrossRef]

20. Barr, F.; Duan, F.; Smith, L.M.; Gustafson, D.; Pitts, M.; Hammond, S.; Gastier-Foster, J.M. Genomic and Clinical Analysis of 2p24 and 12q13-q14 Amplification in Alveolar Rhabdomyosarcoma: A Report from the Children’s Oncology Group. Genes Chromosom. Cancer. 2009, 48, 661–672. [CrossRef]

21. Khan, J.; Simon, R.; Bittner, M.; Chen, Y.; Leighton, S.B.; Pohida, T.; Smith, P.D.; Jiang, Y.; Gooden, G.C.; Trent, J.M.; et al. Gene Expression Profiling of Alveolar Rhabdomyosarcoma with cDNA Microarrays. Cancer Res. 1998, 58, 5009–5013. [PubMed]

22. Davicioni, E.; Finckenstein, F.G.; Shahbazian, V.; Buckley, J.D.; Triche, T.J.; Anderson, M.J. Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of rhabdomyosarcomas. Cancer Res. 2006, 66, 6936–6946. [CrossRef] [PubMed]

23. De Pittà, C.; Tombolan, L.; Albiero, G.; Sartori, F.; Romualdi, C.; Jurman, G.; Carli, M.; Furlanello, C.; Lanfranchi, G.; Rosolen, A. Gene expression profiling identifies potential relevant genes in alveolar rhabdomyosarcoma pathogenesis and discriminates PAX3-FKHR positive and negative tumors. Int. J. Cancer 2006, 118, 2722–2728. [CrossRef] [PubMed]

24. Missiaglia, E.; Williamson, D.; Chisholm, J.; Wirapati, P.; Pierron, G.; Petel, F.; Concordet, J.-P.; Thway, K.; Oberlin, O.; Pritchard-Jones, K.; et al. PAX3/FOXO1 Fusion Gene Status Is the Key Prognostic Molecular Marker in Rhabdomyosarcoma and Significantly Improves Current Risk Stratification. J. Clin. Oncol. 2012, 30, 1670–1677. [CrossRef] [PubMed]

25. Williamson, D.; Missiaglia, E.; De Reyniês, A.; Pierron, G.; Thuille, B.; Palenzuela, G.; Thway, K.; Orbach, D.; Lé, M.; Fréneaux, P.; et al. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J. Clin. Oncol. 2010, 28, 2151–2158. [CrossRef] [PubMed]

26. Missiaglia, E.; Williamson, D.; Chisholm, J.; Wirapati, P.; Pierron, G.; Petel, F.; Concordet, J.-P.; Thway, K.; Oberlin, O.; Pritchard-Jones, K.; et al. Reply to S. Stegmaier et al. J. Clin. Oncol. 2012, 30, 4040–4041. [CrossRef]
27. Stegmaier, S.; Bielack, S.S.; Leuschner, I.; Klingebiel, T.; Koscielniak, E. Questionable Universal Validity of PAX3/FOXO1 Fusion Gene Status As Molecular Marker for Improvement of Risk Stratification in Rhabdomyosarcoma Therapy. *J. Clin. Oncol.* 2012, 30, 4039–4040. [CrossRef] [PubMed]
28. Linardic, C.M. PAX3-FOXO1 fusion gene in rhabdomyosarcoma. *Cancer Lett.* 2008, 270, 10–18. [CrossRef] [PubMed]
29. Xia, S.J.; Holder, D.D.; Pawel, B.R.; Zhang, C.; Barr, F.G. High expression of the PAX3-FKHR oncoprotein is required to promote tumorigenesis of human myoblasts. *Am. J. Pathol.* 2009, 175, 2600–2608. [CrossRef] [PubMed]
30. Marshall, A.D.; Picchione, F.; Geltink, R.I.K.; Grosveld, G.C. PAX3-FOXO1 Induces Up-Regulation of Noxa Sensitizing Alveolar Rhabdomyosarcoma Cells to Apoptosis. *Neoplasia* 2013, 15, 738–748. [CrossRef]
31. Schmitt-Ney, M.; Camussi, G. The PAX3-FOXO1 fusion protein present in rhabdomyosarcoma interferes with normal FOXO activity and the TGF-β pathway. *Plos One* 2015, 10, 1–19. [CrossRef] [PubMed]
32. Tenente, I.M.; Hayes, M.N.; Ignatius, M.S.; McCarthy, K.; Yohe, M.; Sindiri, S.; Gryder, B.; Oliveira, M.L.; Ramakrishnan, A.; Tang, Q.; et al. Myogenic regulatory transcription factors regulate growth in rhabdomyosarcoma. *Elife* 2017, 6, 1–24. [CrossRef] [PubMed]
33. Zhu, B.; Davie, J.K. New insights into signalling-pathway alterations in rhabdomyosarcoma. *Br. J. Cancer* 2015, 112, 227–231. [CrossRef] [PubMed]
34. Cao, L.; Yu, Y.; Bilke, S.; Walker, R.L.; Mayeenuddin, L.H.; Azorsa, D.O.; Yang, F.; Pineda, M.; Helman, L.J.; Meltzer, PS. Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer. *Cancer Res.* 2010, 70, 6497–6508. [CrossRef] [PubMed]
35. Pandey, P.R.; Chatterjee, B.; Olanich, M.E.; Khan, J.; Miettinen, M.M.; Hewitt, S.M.; Barr, F.G. PAX3-FOXO1 is essential for tumour initiation and maintenance but not recurrence in a human myoblast model of rhabdomyosarcoma. *J. Pathol.* 2017, 241, 626–637. [CrossRef] [PubMed]
36. Monti, E.; Fanzani, A. Uncovering metabolism in rhabdomyosarcoma. *Cell Cycle* 2016, 15, 184–195. [CrossRef]
37. Langfelder, P.; Horvath, S. Eigengene networks for studying the relationships between co-expression modules. *Bmc Syst. Biol.* 2007, 1, 54. [CrossRef]
38. Zhang, B.; Genetics, H.; Zhang, B.; Horvath, S. A General Framework for Weighted Gene Co-Expression Network Analysis. *Stat. Appl. Genet. Mol. Biol.* 2005, 4, 1–43. [CrossRef]
39. Fiscon, G.; Conte, F.; Farina, L.; Paci, P. Network-Based Approaches to Explore Complex Biological Systems towards Network Medicine. *Genes* 2018, 9, 437. [CrossRef]
40. Xiang, Y.; Zhang, J.; Huang, K. Mining the tissue-tissue gene co-expression network for tumor microenvironment study and biomarker prediction. *Bmc Genom.* 2013, 14, S4. [CrossRef]
41. Zhang, J.; Lu, K.; Xiang, Y.; Islam, M.; Kotian, S.; Kais, Z.; Lee, C.; Azora, M.; Liu, H.; Parvin, J.D.; et al. Weighted Frequent Gene Co-expression Network Mining to Identify Genes Involved in Genome Stability. *Plos Comput. Biol.* 2012, 8, e1002656. [CrossRef] [PubMed]
42. Zhang, J.; Huang, K. Normalized ImQCM: An Algorithm for Detecting Weak Quasi-Cliques in Weighted Graph with Applications in Gene Co-Expression Module Discovery in Cancers. *Cancer Inform.* 2016, 13, 137–146. [CrossRef] [PubMed]
43. Barr, F.; Smith, L.; Lynch, J.C.; Strzelecki, D.; Parham, D.; Qualman, S.; Breifeld, P. Examination of Gene Fusion Status in Archival Samples of Alveolar Rhabdomyosarcoma Entered on the Intergroup Rhabdomyosarcoma Study-III Trial: a Report from the Children’s Oncology Group. *J. Mol. Diagn.* 2006, 8, 202–208. [CrossRef] [PubMed]
44. Davis, S.; Meltzer, P.S. GEOquery: A bridge between the Gene Expression Omnibus (GEO) and Bioconductor. *Bioinformatics* 2007, 23, 1846–1847. [CrossRef] [PubMed]
45. Huber, W.; Carey, V.J.; Gentleman, R.; Anders, S.; Carlson, M.; Carvalho, B.S.; Bravo, H.C.; Davis, S.; Gatto, L.; Girke, T.; et al. Orchestrating high-throughput genomic analysis with Bioconductor. *Nat. Methods* 2015, 12, 115–121. [CrossRef] [PubMed]
46. Huang, Z.; Zhang, J.; Huang, K.; Han, Z. ImQCM: An Algorithm for Gene Co-Expression Analysis. Available online: https://github.com/huangzhii/ImQCM (accessed on 15 May 2019).
47. *R Core Team R: A Language and Environment for Statistical Computing*; R foundation for Statistical Computing: Vienna, Austria, 2018.
48. Zhao, P.; Zhang, C.Q. A new clustering method and its application in social networks. *Pattern Recognit. Lett.* **2011**, *32*, 2109–2118. [CrossRef]

49. Oksanen, J.; Blanchet, F.G.; Friendly, M.; Kindt, R.; Legendre, P.; McGlinn, D.; Minchin, P.R.; O’Hara, R.B.; Simpson, G.L.; Solymos, P.; et al. Vegan: Community Ecology Package. Available online: https://github.com/vegandevs/vegan (accessed on 15 May 2019).

50. Seshan, V.E.; Ols, A. DNAcopy: DNA Copy Number Data Analysis. Available online: https://github.com/veseshan/DNAcopy (accessed on 15 May 2019).

51. Mermel, C.H.; Schumacher, S.E.; Hill, B.; Meyerson, M.L.; Beroukhim, R.; Getz, G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. *Genome Biol.* **2011**, *12*, R41. [CrossRef] [PubMed]

52. Laddha, S.V.; Ganesan, S.; Chan, C.S.; White, E. Mutational Landscape of the Essential Autophagy Gene BECN1 in Human Cancers. *Mol. Cancer Res.* **2014**, *12*, 485–490. [CrossRef]

53. Petak, I.; Douglas, L.; Tillman, D.M.; Vernes, R.; Houghton, J.A. Pediatric Rhabdomyosarcoma Cell Lines Are Resistant to Fas-induced Apoptosis and Highly Sensitive to TRAIL-induced Apoptosis. *Clin. Cancer Res.* **2000**, *6*, 4119–4127.

54. Langfelder, P.; Horvath, S. WGCNA: An R package for weighted correlation network analysis. *Bmc Bioinform.* **2008**, *9*, 559. [CrossRef]

55. Heinicke, U.; Haydn, T.; Kehr, S.; Vogler, M.; Fulda, S. BCL-2 selective inhibitor ABT-199 primes rhabdomyosarcoma cells to histone deacetylase inhibitor-induced apoptosis. *Oncogene* **2018**, *37*, 5325–5339. [CrossRef] [PubMed]

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).